logo
An explosion of sea urchins threatens to push coral reefs in Hawaii ‘past the point of recovery'

An explosion of sea urchins threatens to push coral reefs in Hawaii ‘past the point of recovery'

CTV News21-06-2025

Expanding numbers of sea urchins threaten the population of coral reefs in Hawaii, research says. (Pexels/Kindel Media)
The turquoise water of Hōnaunau Bay in Hawaii, an area popular with snorkelers and divers, is teeming with spiny creatures that threaten to push the coral reef 'past the point of recovery,' new research has found.
Sea urchin numbers here are exploding as the fish species that typically keep their populations in check decline due to overfishing, according to the study, published last month in the journal PLOS ONE. It's yet another blow to a reef already suffering damage from pollution as well as climate change-driven ocean heat waves and sea level rise.
Kelly J. van Woesik, a researcher at the North Carolina State University Center for Geospatial Analytics and a study author, first noticed unusually high numbers of sea urchins on snorkeling trips. 'I knew there was a story to be told,' she said.
She and her fellow researchers used data from scuba surveys and images taken from the air to track the health of the reef.
'We found on average 51 urchins per square metre, which is among the highest recorded densities on coral reefs anywhere in the world,' van Woesik said.
Sea urchins are small marine invertebrates, characterized by their spiny bodies and found in oceans around the world. They play a useful role in preventing algae overgrowth, which can choke off oxygen to coral. However, they also eat the reef and too many of them can cause damaging erosion.
In Hōnaunau Bay, the coral is already struggling to reproduce and grow due to ocean heat and water pollution, leaving it even more vulnerable to the erosion inflicted by sea urchins.
Its rate of growth has plummeted according to the study.
Reef growth is typically measured by the amount of calcium carbonate — the substance which forms coral skeletons — it produces per square metre each year.
The reef in Hōnaunau Bay is growing 30 times more slowly than it did four decades ago, according to the study. Production levels were around 15 kilograms (33 pounds) per square
in parts of Hawaii, signaling a healthy reef, according to research in the 1980s.
Today, the reef in Hōnaunau Bay produces just 0.5 kilograms (1.1 pounds) per square metre.
To offset erosion from urchins, at least 26 per cent of the reef surface must be covered by living corals – and even more coral cover is necessary for it to grow.
Gregory Asner, an ecologist at Arizona State University and study author, said what was happening in this part of Hawaii was emblematic of the mounting pressures facing reefs throughout the region.
'For 27 years I have worked in Hōnaunau Bay and other bays like it across Hawaii, but Hōnaunau stood out early on as an iconic example of a reef threatened by a combination of pressures,' he said, citing warming ocean temperatures, pollution from tourism and heavy fishing.
The implications of coral decline are far-reaching. Coral reefs are sometimes dubbed the 'rainforests of the sea' because they support so much ocean life. They also play a vital role protecting coastlines from storm surges and erosion.
'If the reef can't keep up with sea-level rise, it loses its ability to limit incoming wave energy,' said van Woesik. 'That increases erosion and flooding risk of coastal communities.'
Kiho Kim, an environmental science professor at American University, who was not involved in the study, said the findings highlight the fragility of reef ecosystems under stress.
'Dramatic increases in any species indicate an unusual condition that has allowed them to proliferate,' Kim said. That imbalance can undermine diversity and reduce the reef's ability to provide essential ecosystem services including food security and carbon storage, he told CNN.
Despite the challenges, researchers emphasize that the reef's future is not sealed. Local groups in Hōnaunau are working to reduce fishing pressure, improve water quality and support coral restoration.
'These reefs are essential to protecting the islands they surround,' van Woesik said. 'Without action taken now, we risk allowing these reefs to erode past the point of no return.'
By Isabelle Rodney.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Traumatic Brain Injury Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment
Traumatic Brain Injury Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment

Globe and Mail

time11 hours ago

  • Globe and Mail

Traumatic Brain Injury Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment

DelveInsight's ' Traumatic Brain Injury Pipeline Insight 2025 ' report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Traumatic Brain Injury Treatment Landscape. Click here to read more @ Traumatic Brain Injury Pipeline Outlook Key Takeaways from the Traumatic Brain Injury Pipeline Report In June 2025, Hope Biosciences announced a study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure, neurocognitive/functional outcomes, and neuroinflammation after traumatic brain injury. In June 2025, Merz Pharmaceuticals GmbH conducted a study is to determine whether a single treatment with administration of 400 Units NT 201 (botulinum toxin) is superior to placebo (no medicine) for the treatment of lower limb spasticity caused by stroke or traumatic brain injury (Main Period). Participants will be assigned to the treatment groups by chance and neither the participants nor the research staff who interact with them will know the allocation. In June 2025, Ipsen organized a study is to assess the safety and efficacy of increasing doses of IPN10200 with the aim to evaluate the Pharmacodynamics (PD) profile of IPN10200 and to establish the total IPN10200 doses(s) that offer the best efficacy/safety profile when used for the treatment of Adult upper limb (AUL) spasticity. DelveInsight's Traumatic Brain Injury pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Traumatic Brain Injury treatment. The leading Traumatic Brain Injury Companies such as Oragenics, Inc, SHINKEI Therapeutics, Inc, AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, Biomed Industries, Inc, BioArctic, Tiziana Life Sciences, TikoMed AB, Levolta Pharmaceuticals, Inc, Boulder BioScience, LLC, International Stem Cell Corporation, Revalesio Corporation, Teleport Pharmaceuticals and others. Promising Traumatic Brain Injury Pipeline Therapies such as Flortaucipir F18, NE3107, Amantadine Hydrochloride, VAS203, SB623 cells, Rivastigmine, VAS203, Dexanabinol and others. Discover groundbreaking developments in Traumatic Brain Injury Therapies! Gain in-depth knowledge of key Traumatic Brain Injury Emerging Drugs, and market opportunities @ Traumatic Brain Injury Clinical Trials Assessment Traumatic Brain Injury Emerging Drugs Profile ONP-002: Oragenics, Inc. ONP-002 is a First-in-Class Enantiomeric-Neurosteroid being developed for the treatment of mild Traumatic Brain Injury (mTBI) aka concussion. ONP-002 diffuses intracellularly to induce steroid receptors found in neurons, glia, and the endothelium of the blood brain-barrier. The induction of the ONP-002 receptors activates multiple gene response elements leading to the production of mRNA transcripts and subsequently proteins that reduce inflammation, oxidative stress, and swelling. In addition, ONP-002 induces macro-autophagy to reduce the build-up of extra- and intra-cellular debris that can cause chronic neurological diseases associated with dementia. Currently, the drug is in the Phase II stage of its development for the treatment of Traumatic Brain Injury. MR-301: SHINKEI Therapeutics, Inc MR-301 – Amantadine HCl Intravenous (IV) Solution is SHINKEI's most advanced program. Amantadine HCl is one of the most commonly prescribed off-label medications for patients with prolonged disorders of consciousness after TBI. Amantadine HCl increases dopamine availability in the synapse by inhibiting the activation of dopaminergic receptors. Amantadine HCl has been approved as a prescription oral product in the U.S since 1966 and, as such, has a long history of safe use in the U.S. and globally. Preliminary studies in preclinical models and patients with TBI have suggested that amantadine may promote functional recovery with high levels of safety. Currently, the drug is in Phase II stage of its development for the treatment of Traumatic Brain Injury. ACD 856: AlzeCure ACD 856 is a small molecule, positive allosteric modulator of Trk receptors, which mediate the effects of BDNF, NGF, and other neurotrophic factors. ACD856 increases the kinase activity of Trk receptors and enhances the effects of BDNF or NGF on survival, neuronal function, and synaptic plasticity. This is intended to make up for loss of BDNF and NGF signaling that occurs in AD. This compound is taken orally. The compound improves mitochondrial function and increases BDNF expression in cells, and shows antidepressant activity in mice. Currently, the drug is in Phase I stage of its development for the treatment of Traumatic Brain Injury. AP-188: Algernon Pharmaceutical AP-188 (N,N-Dimethyltryptamine, or DMT) is a potential treatment for stroke and traumatic brain injury (TBI) recovery. DMT is a naturally occurring compound that is part of the tryptamine family, which also includes psilocybin and psilocin. DMT is naturally occurring and found in plants and animals and is expressed naturally in humans in times of great physiological stress, including cardiac arrest and childbirth. It is assumed to have roles in cell protection, regeneration, and immunity as well. The drug is a sigma receptor agonist, and some evidence points to sigma receptor binding as a critical factor in the drug's protective actions. Psychedelic drugs as a class have also demonstrated an ability to promote neuritogenesis both in vivo and in vitro. The effects are believed to be through agonism of the 5-HT2A receptor, although other receptors, including sigma, may be involved. DMT increases expression of Brain Derived Neurotropic Factor (BDNF), which promotes neuroplasticity: a key factor in the brain's ability to form and reorganize synaptic connections, which are needed for healing following a brain injury. DMT is also known to bind to a number of other receptors, including various 5-HT, dopamine, adrenergic, and trace amine receptors. Currently, the drug is in Phase I stage of its development for the treatment of Traumatic Brain Injury. The Traumatic Brain Injury Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Traumatic Brain Injury with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Traumatic Brain Injury Treatment. Traumatic Brain Injury Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Traumatic Brain Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Traumatic Brain Injury market Stay informed about the Traumatic Brain Injury pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Traumatic Brain Injury Unmet Needs Traumatic Brain Injury Companies Oragenics, Inc, SHINKEI Therapeutics, Inc, AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, Biomed Industries, Inc, BioArctic, Tiziana Life Sciences, TikoMed AB, Levolta Pharmaceuticals, Inc, Boulder BioScience, LLC, International Stem Cell Corporation, Revalesio Corporation, Teleport Pharmaceuticals and others. Traumatic Brain Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Traumatic Brain Injury Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Transform your understanding of the Traumatic Brain Injury Pipeline! See the latest progress in drug development and clinical research @ Traumatic Brain Injury Market Drivers and Barriers, and Future Perspectives Scope of the Traumatic Brain Injury Pipeline Report Coverage- Global Traumatic Brain Injury Companies- Oragenics, Inc, SHINKEI Therapeutics, Inc, AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, Biomed Industries, Inc, BioArctic, Tiziana Life Sciences, TikoMed AB, Levolta Pharmaceuticals, Inc, Boulder BioScience, LLC, International Stem Cell Corporation, Revalesio Corporation, Teleport Pharmaceuticals and others. Traumatic Brain Injury Pipeline Therapies- Flortaucipir F18, NE3107, Amantadine Hydrochloride, VAS203, SB623 cells, Rivastigmine, VAS203, Dexanabinol and others. Traumatic Brain Injury Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Traumatic Brain Injury Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Research-Access the Full Traumatic Brain Injury Pipeline Analysis Today! @ Traumatic Brain Injury Drugs and Companies Table of Contents Introduction Executive Summary Traumatic Brain Injury: Overview Pipeline Therapeutics Therapeutic Assessment Traumatic Brain Injury– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Drug Name: Company Name Drug profiles in the detailed report….. Mid Stage Products (Phase II) ONP-002: Oragenics, Inc. Drug profiles in the detailed report….. Early Stage Products (Phase I) ACD 856: AlzeCure Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Traumatic Brain Injury Key Companies Traumatic Brain Injury Key Products Traumatic Brain Injury- Unmet Needs Traumatic Brain Injury- Market Drivers and Barriers Traumatic Brain Injury- Future Perspectives and Conclusion Traumatic Brain Injury Analyst Views Traumatic Brain Injury Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

Clene (NASDAQ: CLNN) Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs
Clene (NASDAQ: CLNN) Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs

Globe and Mail

time17 hours ago

  • Globe and Mail

Clene (NASDAQ: CLNN) Advances Regulatory Strategy for CNM-Au8 with FDA Meetings Scheduled for ALS and MS Programs

Clene (NASDAQ: CLNN) announced key regulatory developments following a Type C meeting with the FDA, where it received feedback on its statistical analysis plan (SAP) for evaluating neurofilament light (NfL) biomarker data from its Expanded Access Protocol for ALS. The company has resubmitted a revised SAP and anticipates FDA acceptance this summer, with NfL analyses scheduled for early Q4 2025 to support a potential NDA submission under the accelerated approval pathway. Clene also confirmed two additional FDA meetings in Q3 2025: one to assess long-term ALS survival data for accelerated approval consideration and another End-of-Phase 2 Type B meeting to review Phase 2 MS trial results and discuss a Phase 3 study targeting cognitive improvement. To view the full press release, visit About Clene Inc. Clene (along with its subsidiaries, 'Clene') and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit About BioMedWire BioMedWire ('BMW') is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. To receive SMS alerts from BioMedWire, 'Biotech' to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: BioMedWire Austin, Texas 512.354.7000 Office Editor@ BioMedWire is powered by IBN

Avant Technologies and JV Partner, Ainnova, Prepare for Key FDA Milestone with Next Week's Pre-Submission Meeting
Avant Technologies and JV Partner, Ainnova, Prepare for Key FDA Milestone with Next Week's Pre-Submission Meeting

Globe and Mail

timea day ago

  • Globe and Mail

Avant Technologies and JV Partner, Ainnova, Prepare for Key FDA Milestone with Next Week's Pre-Submission Meeting

LAS VEGAS , June 30, 2025 /CNW/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that Ainnova and its Contract Research Organization, Fortrea, will use this week to make final preparations for the company's pre-submission meeting with the U.S. Food and Drug Administration (FDA) next week. The pre-submission meeting with Ainnova's executives and its CRO is set for Monday, July 7. The FDA meeting will allow the Company to discuss its planned clinical trial of Ainnova's Vision AI platform in the early detection of diabetic retinopathy. These meetings will give the team the direction it needs for a successful clinical trial and to support the Company's FDA 510(k) submission to obtain clearance from the FDA to market the Vision AI technology in the United States . Vinicio Vargas , Chief Executive Officer at Ainnova and a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, said, "We're approaching a key milestone. We've been preparing thoroughly with the support of an experienced CRO and expert regulatory advisors, and we're optimistic about the outcome. "Diabetic retinopathy is the number one cause of preventable blindness worldwide. That's unacceptable—and we believe technology can change that. But this is just the beginning. Retinal screening offers a gateway to detecting many systemic conditions early—like Alzheimer's, cardiovascular disease, and more. "We're committed to pushing the boundaries of preventive care, improving both life expectancy and quality of life for people around the world. That's the mission behind everything we do." Ainnova will use this pre-submission meeting to determine a host of items, including the ideal number of clinical sites, the number of total patients needed, and to learn if the FDA will approve the clinical trial protocol for the planned trial. These are all crucial for both Avant and Ainnova in determining the exact costs and a timetable. AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include the U.S., where the FDA regulates drug and medical device development, so the success of Ainnova's interactions with the FDA are paramount to marketing the technology portfolio in the United States. Entering the U.S. market will unlock significant commercial potential, and this early engagement with the FDA ensures AAC can do so with speed, credibility, and a validated product. About Ainnova Tech, Inc. Ainnova is a Nevada -based healthtech startup with headquarters in San Jose, Costa Rica , and Houston, Texas . Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies, Inc. Avant Technologies Inc. is an emerging technology company developing solutions in healthcare using artificial intelligence and biotechnologies. With a focus on pushing the boundaries of what is possible in AI and biotechnology, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store